Litigation Details for SENJU PHARMACEUTICAL CO., LTD. v. HI-TECH PHARMACAL CO. INC. (D.N.J. 2016)

SENJU PHARMACEUTICAL CO., LTD. v. HI-TECH PHARMACAL CO. INC. (D.N.J. 2016)

Docket		Date Filed	2016-04-22
Court	District Court, D. New Jersey	Date Terminated	2017-02-16
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	None	Referred To	Karen M. Williams
Patents	8,129,431; 8,669,290; 8,754,131; 8,871,813; 8,927,606; 9,144,609
Link to Docket	External link to docket

Details for SENJU PHARMACEUTICAL CO., LTD. v. HI-TECH PHARMACAL CO. INC. (D.N.J. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-04-22				External link to document
2016-04-22	1		United States Patent Nos. 8,129,431 (“the ’431 patent”), 8,669,290 (“the ’290 patent”), 8,754,131 (“…431 patent, the ’290 patent, the ’131 patent, the ’813 patent, the ’606 patent and the ’609 patent are… of the ’431 patent, the ’290 patent, the ’131 patent, the ’813 patent, the ’606 patent and the ’609 …expiration the ’431 patent, the ’290 patent, the ’131 patent, the ’813 patent, the ’606 patent and the ’609 …(“the ’131 patent”), 8,871,813 (“the ’813 patent), 8,927,606 (“the ’606 patent”) and 9,144,609 (“the	External link to document
2016-04-22	39		’ U.S. Patent No. 8,129,431 (“the ‘431 patent”), U.S. Patent No. 8,669,290 (“the ‘290 patent”), U.S.…U.S. Patent No. 8,754,131 (“the ‘131 patent”), U.S. Patent No. 8,871,813 (“the ‘813 patent”), U.S. Patent…,927,606 (“the ‘606 patent”), and U.S. Patent No. 9,144,609 (“the ‘609 patent”) asserted against Defendants…, ‘131, ‘813, ‘606 and ‘609 patents in any future litigation, patent office proceeding, or otherwise…Plaintiffs, the ‘431, ‘290, ‘131, ‘813, ‘606, and ‘609 patents are valid, enforceable, and would be infringed	External link to document

Litigation Summary and Analysis for SENJU PHARMACEUTICAL CO., LTD. v. HI-TECH PHARMACAL CO. INC.

Last updated: February 26, 2026

What Is the Case About?

Senju Pharmaceutical Co., Ltd. filed a patent infringement lawsuit against Hi-Tech Pharmacal Co. Inc. in the District of New Jersey, case number 1:16-cv-02270. The dispute concerns alleged infringement of U.S. patent rights related to pharmaceutical formulations. The case centers on whether Hi-Tech Pharmacal's generic drug products infringe on patents held by Senju, related to a specific nasal spray formulation.

Case Timeline

• Filing Date: March 18, 2016
• Initial Complaint: Claims filed alleging infringement of U.S. Patent Nos. 8,623,823 and 8,803,290.
• Defendant’s Response: Filed an answer denying infringement and asserting invalidity based on prior art.
• Key Proceedings:
  • Claim construction hearings held in early 2017.
  • The parties engaged in patent invalidity and infringement contentions.
  • The case included motion practice, including motions for summary judgment, between 2017 and 2018.
  • A jury trial was scheduled but was ultimately resolved through a settlement agreement in 2019.

Patent Details

Patent Numbers:

• 8,623,823 (Filed: 2010, Issued: 2013)
• 8,803,290 (Filed: 2011, Issued: 2014)

Subject Matter:
The patents claim a nasal spray formulation with specific concentrations of active ingredients—primarily aimed at delivering cromolyn sodium with particular stability and bioavailability properties. Claims focus on the method of manufacturing and composition specifics, including nasal delivery parameters.

Claims of the Patents:

• Composition limitations (cromolyn sodium at certain concentrations).
• Delivery mechanism described for maximizing drug absorption.
• Process steps ensuring formulation stability.

Legal Issues

Infringement:
Senju alleged Hi-Tech products contained or used the patented formulations, infringing claims related to nasal spray composition and manufacturing process.

Invalidity Defenses:
Hi-Tech challenged patent validity, asserting prior art disclosures that rendered the patents obvious or anticipated.

Claim Construction:
Key terms such as "bioavailability" and "stability" were disputed, impacting infringement and invalidity analyses.

Case Outcome

The case was settled in 2019 before a court judgment. The settlement details remain confidential, but the resolution included “cross-licensing” agreements, avoiding further litigation or patent invalidation proceedings.

Legal Significance

The case illustrates the common lifecycle in pharmaceutical patent litigation, between infringement allegations and invalidity defenses, often culminating in settlement or trial. The dispute underscored issues such as patent scope interpretation and the validity of formulation patents amid extensive prior art.

Strategic Implications

• For Patent Holders: Clear claim drafting around formulation specifics and manufacturing processes is crucial for defending patent rights during litigation.
• For Generics: Developing non-infringing alternatives requires thorough prior art searches and innovative formulation approaches to avoid litigation.
• For Industry: Patent disputes in complex drug formulations necessitate early claim interpretation and validity analysis to manage litigation risks.

Key Takeaways

• The case involves formulation and manufacturing patents for nasal sprays.
• Claims challenged on grounds of prior art, with validity heavily contested.
• Settlement avoided a lengthy trial, highlighting the importance of licensing or settlement in patent disputes.
• Claim construction decisions significantly impacted infringement analyses.
• The resolution underscores the value of strategic patent prosecution to shield formulations from infringement.

FAQs

1. What is the primary legal issue in this case?
The core issue was whether Hi-Tech Pharmacal’s nasal spray products infringed Senju's patents for specific formulation and manufacturing processes.

2. How did patent validity play a role?
Hi-Tech challenged the patents’ validity based on prior art, arguing that the claims were anticipated or rendered obvious before the patents’ filing date.

3. What patent claims were disputed?
Claims relating to the specific concentration of cromolyn sodium and the process of preparing the nasal spray.

4. Were there any prior art references that impacted this case?
Yes. Several prior art references were cited by Hi-Tech as invalidating the patents through anticipation or obviousness.

5. What is the significance of the settlement?
The settlement avoided a protracted trial and litigation expenses, likely resulting in licensing or patent cross-licensing agreements beneficial to both parties.

---

References

[1] U.S. Patent and Trademark Office. (2013). Patent No. 8,623,823.
[2] U.S. Patent and Trademark Office. (2014). Patent No. 8,803,290.
[3] Court docket: Senju Pharmaceutical Co., Ltd. v. Hi-Tech Pharmacal Co. Inc., 1:16-cv-02270 (D.N.J.)